The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis <i>in vitro</i>

Paul M. Clément(Universitair Ziekenhuis Leuven), Myung Hee Park(National Institutes of Health), Edith C. Wolff(National Institutes of Health), Hartmut M. Hanauske‐Abel(National Institutes of Health), Hynda K. Kleinman(National Institute of Dental and Craniofacial Research)

International Journal of Cancer

June 13, 2002

10.1002/ijc.10515

Cited by 136

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

|Journal of Clinical Oncology|2009|573

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

|The Lancet Oncology|2016|504

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

|Journal of Clinical Oncology|2010|445

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

|The Lancet|2017|401